Charles River Laboratories International Inc
CRL: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| $537.00 | Rgjknzj | Vqzwykvv |
Charles River Rebounds From COVID-19 Pandemic; Raising FVE to $162 Yet Shares Remain Expensive
/s3.amazonaws.com/arc-authors/morningstar/ca9ef979-0207-4e37-b392-91618ebc1841.jpg)
After taking a fresh look at Charles River Laboratories, we’ve slightly raised our fair value estimate to $162 per share from $161, which is primarily attributed to the time value of money since our last update. We continue to have a positive outlook for 2021 and we anticipate about 13% revenue growth and 16% adjusted EPS growth. Nevertheless, we view shares as very expensive. We’re maintaining our narrow moat and stable moat trend ratings.